scholarly article | Q13442814 |
P356 | DOI | 10.1136/BMJ.E3012 |
P698 | PubMed publication ID | 22549057 |
P2093 | author name string | Ingrid Torjesen | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | eye disease | Q3041498 |
bevacizumab | Q413299 | ||
P304 | page(s) | e3012 | |
P577 | publication date | 2012-05-01 | |
P1433 | published in | The BMJ | Q546003 |
P1476 | title | Why using Avastin for eye disease is so difficult | |
P478 | volume | 344 |
Q24202071 | Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema |
Q51034328 | Bevacizumab versus ranibizumab: why are we not playing the joker? |
Q34544415 | Essential medicines for universal health coverage |
Q58804239 | Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study |
Q36461851 | The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package |
Search more.